Veterinary Medicines Have Received Regulatory Approval
The Committee for Veterinary Medicinal Products adopted positive opinions for several new and existing products.
Updated on Oct. 10, 2026 in Veterinary Medicine
Live Poll
Do you trust that veterinary medicine regulators prioritize animal safety effectively when approving new treatments?
The Committee for Veterinary Medicinal Products has issued positive opinions for various marketing authorizations, including for Bovilis Lumpyvax and Stemyca. The committee also concluded a referral procedure confirming a positive benefit-risk balance for Vetmedin oral solution for dogs.
Why it matters
These regulatory actions ensure that veterinary medicinal products meet established safety and efficacy standards before entering the market. The referral procedure for Vetmedin addressed specific concerns regarding its effectiveness, providing clarity for both veterinarians and pet owners.
The committee adopted two scientific advice reports for products intended for Atlantic salmon. Additionally, the committee confirmed a concentration of 1.5 mg/ml for the approved Vetmedin oral solution for dogs.
The players
Committee for Veterinary Medicinal Products
This is the body responsible for preparing the agency's opinions on questions relating to veterinary medicinal products within the European Union.
European Commission
This is the executive branch of the European Union responsible for proposing legislation and implementing decisions regarding regulatory standards.
The details
The committee reviewed data and requested clarifications under Article 54(8) of Regulation (EU) 2019/6 to reach these conclusions. Clarifications for Vetmedin were specifically requested by the European Commission following a lack of consensus among Member States.
Timeline
The committee meeting took place from October 6-8, 2026.
Culture Shift
These regulatory decisions reflect the ongoing standardization of veterinary oversight required under Regulation (EU) 2019/6. The committee utilized the evaluation and clarification framework established by this regulation to process the latest batch of product applications.
These decisions impact the availability of specific treatments for pets and livestock in the European Union. Pet owners and veterinarians can expect continued access to authorized products like Vetmedin, now confirmed through the latest safety reviews.
The takeaway
These actions highlight the importance of rigorous, centralized review processes in maintaining the safety of animal health products. Professionals should stay informed regarding these authorization updates to ensure they are using the most current, verified treatments.
Further reading
Find more details on regulatory updates in the Veterinary Medicine section.
More information
For a detailed overview of current safety data, view the List of veterinary medicine safety signals.
Live Poll
Do you trust that veterinary medicine regulators prioritize animal safety effectively when approving new treatments?
